Almirall Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Carlos Gallardo Piqué

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	5.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Carlos Gallardo Piqué (52 yo)

2.8yrs

Permanencia

€50,000

Compensación

Mr. Carlos Gallardo Piqué serves as President at Almirall S. A. since January 2024. He has been Chairman of Board at Almirall, S.A. since May 06, 2022. He serves as Chief Executive Officer at Almirall, S.A...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Carlos Gallardo Piqué	CEO, President	2.8yrs	€50.00k	sin datos
Michael McClellan	CFO & Member of Management Board	5yrs	sin datos	sin datos
Eloi Crespo Cervera	Chief Industrial Operations Officer & Member of Management Board	no data	sin datos	sin datos
Esteve Conesa Panicot	Chief People & Culture Officer and Member of Management Board	no data	sin datos	sin datos
Volker Koscielny	Chief Medical Officer & Member of Management Board	4.8yrs	sin datos	sin datos
Karl Ziegelbauer	Chief Scientific Officer & Member of Management Board	3.8yrs	sin datos	sin datos
Paolo Cionini	Chief Commercial Officer Europe & International and Member of Management Board	3.8yrs	sin datos	sin datos
Isabel Gomes	Company Vice Secretary	2.8yrs	sin datos	sin datos
Mercedes Diz Lopez	Chief Marketing Officer & Member of Management Board	2.8yrs	sin datos	sin datos
Paul Rittman	Member of Management Board and President & GM of Almirall US	less than a year	sin datos	sin datos
Pablo del Fraile	Senior Director of Investor Relations	no data	sin datos	sin datos
Xavier Alba	Acting CSO and Head of R&D	no data	sin datos	sin datos

3.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de E2Z se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Carlos Gallardo Piqué	CEO, President	10.3yrs	€50.00k	sin datos
Sidney Taurel	Member of Global Advisory Board-Spain	15.8yrs	sin datos	sin datos
Enrique de Leyva Perez	Vice-Chair & Lead Independent Director	5.8yrs	sin datos	0.0098% € 178.3k
Karin Louise Dorrepaal	External Independent Director	11.8yrs	€122.00k	sin datos
Eva-Lotta Coulter	Independent Director	4.2yrs	sin datos	sin datos
Ruud Dobber	Independent Director	3.4yrs	sin datos	sin datos
Ugo Francesco	Independent Director	less than a year	sin datos	sin datos
Antonio Gallardo Torrededia	Proprietary Director	10.3yrs	€50.00k	sin datos
Seth Orlow	External Independent Director	8.5yrs	sin datos	sin datos
Alexandra Kimball	Independent Director	4.2yrs	sin datos	sin datos
Eva Iglesias	Independent Director	less than a year	sin datos	sin datos

5.8yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de E2Z se considera experimentada (5.8 años de antigüedad promedio).

Almirall Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Almirall, S.A., Annual General Meeting, May 10, 2024

Almirall, S.A., Annual General Meeting, May 05, 2023

Almirall, S.A. Announces Executive Changes

Almirall, S.A. Announces Executive Changes

Almirall, S.A. Announces Promotion of Pablo Alvarez as President of Almirall US

Recent updates

Third quarter 2024 earnings released

Almirall, S.A. Reiterates Earnings Guidance for Full Year 2024

Second quarter 2024 earnings released

Almirall, S.A. Reiterates Financial Guidance for Full Year 2024

Insufficient new directors

Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year

First quarter 2024 earnings released

Almirall, S.A. Provides Earnings Guidance for Full Year 2024

Almirall, S.A., Annual General Meeting, May 10, 2024

Full year 2023 earnings released: €0.20 loss per share (vs €0.024 profit in FY 2022)

Almirall, S.A. Provides Earnings Guidance for the Year 2024

Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis

Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022)

Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024

Almirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque Psoriasis

Now 20% undervalued

New minor risk - Shareholder dilution

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released

Almirall Launches Nina, the First Series to Highlight the Major Impact of Psoriasis on Patient’s Wellbeing

Almirall, S.A. has completed a Follow-on Equity Offering in the amount of €199.999993 million.

First quarter 2023 earnings released

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: €0.02 (vs €0.23 loss in FY 2021)

Almirall, S.A., Annual General Meeting, May 05, 2023

Now 20% undervalued

Now 20% undervalued after recent price drop

Almirall, S.A. to Report Nine Months, 2023 Results on Nov 16, 2023

Almirall, S.A. Maintains Earnings Guidance for the Full Year of 2022

Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Lebrikizumab in Atopic Dermatitis

Almirall, S.A. Announces the 31st EADV Congress the Results from TRIBUTE, an Interventional Phase IV Clinical Study

Almirall, S.A. Announces New Detailed Results from Phase 3 Monotherapy Studies in Atopic Dermatitis

Second quarter 2022 earnings released: EPS: €0.039 (vs €0.40 loss in 2Q 2021)

Almirall, S.A.(BME:ALM) dropped from Madrid Ibex 35 Index

Happify Health and Almirall, S.A. Go Live with Digital Solution to Support Psoriasis Patients

Almirall, S.A. Announces Topline Results from One-Year Analyses of the Efficacy and Safety of Lebrikizumab

Almirall, S.A. Announces Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

Now 22% undervalued

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Almirall, S.A. Announces Executive Changes

Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp

Almirall Announces Results for Atopic Dermatitis in Third Phase 3 Study

Almirall, S.A. Launches Klisyri (Tirbanibulin) for the Treatment of Actinic Keratosis in Europe

Second quarter 2021 earnings released: €0.40 loss per share (vs €0.036 loss in 2Q 2020)

Almirall, S.A. Receives European Commission Approval of Klisyri® (Tirbanibulin)

Almirall and MC2 Therapeutics Announce Completion of Decentralized Procedure in Europe for the Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Adults

Almirall Receives Positive CHMP Opinion for Klisyri®? (Tirbanibulin), an Innovative Topical Treatment for Actinic Keratosis

First quarter 2021 earnings released: EPS €0.17 (vs €0.28 in 1Q 2020)

Full year 2020 earnings released: EPS €0.42 (vs €0.61 in FY 2019)

Revenue misses expectations

Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis

Almirall and MC2 Therapeutics Enters a License, Collaboration and Commercialization Agreement for European Rights to Wynzora® Cream for treatment of Plaque Psoriasis

Almirall, S.A. Announces New Publication in the British Journal of Dermatology of ILUMETRI

Almirall, S.A. Announces Executive Changes

Almirall and Happify Health Enter into Strategic Partnership to Develop Evidence-Supported Digital Therapeutics Solutions for Psoriasis Patients

New 90-day high: €11.71

Almirall, S.A. and Tyris Therapeutics Enter into Strategic Partnership to Develop Next Generation Gene Therapies

New 90-day high: €11.33

Almirall, S.A. Announces U.S. Food and Drug Administration Approval of Klisyri® (Tirbanibulin), A New Innovative Topical Treatment for Actinic Keratosis

Popit and Almirall Start Offering New Support Tool to Help Psoriasis Patients

Revenue beats expectations

Third quarter 2020 earnings released: EPS €0.087

Almirall, S.A. Announces Promotion of Pablo Alvarez as President of Almirall US

Almirall, S.A. Announces Resignation of Peter Guenter as Chief Executive Officer at the End of the Year

Almirall, S.A. Announces Full 5 Year Data Analysis from Two Phase III Clinical Studies, reSURFACE 1 and reSURFACE2 of ILUMETRI

New 90-day low: €8.97

Almirall, S.A. Announces Approval of the Reimbursed Price for Ilumetri® (Tildrakizumab) in France for the Treatment of Adult Patients with Severe Chronic Plaque Psoriasis

Almirall, S.A. and the University of Dundee Announce Multi-Target Research Collaboration to Develop Novel Targeted Protein Degraders Medicines